Novartis (NVS)
(Delayed Data from NYSE)
$115.30 USD
+1.56 (1.37%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $115.07 -0.23 (-0.20%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Novartis AG has a PEG ratio of 1.64 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.24.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NVS 115.30 +1.56(1.37%)
Will NVS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVS
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
NVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Here's Why Novartis (NVS) is a Strong Value Stock
Other News for NVS
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Private Markets: Scale rival Surge AI in talks for funding at $25B value
Trump Trade: Trump signs executive order raising tariff on Canada to 35%
Market Today: Amazon (AMZN) and Apple (AAPL) Lead Earnings Surge